Future directions for pediatric and young adult bone sarcoma.
Joseph
J
Finney
Paul M
PM
Kent
Marta
M
Batus
D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy / Q000379:methods; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors; D012509:Sarcoma / Q000628:therapy*; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D017526:Receptor, IGF Type 1